Northern Ireland
Almac has secured planning permission for major expansion plans that could potentially see the company create over 500 jobs during the next five years. The global company which provides integrated research, development and manufacturing services to pharmaceutical and biotech companies internationally, has experienced a substantial rate of growth at its Craigavon headquarters. Anticipating future growth requirements, Almac has acquired an adjacent 5.4 acre site and will shortly embark on the first phase of development there.
In 2008 staff numbers in the UK rose by 15% to 1,426 and in the US by 10% to 762. The company also announced the creation of 128 new graduate and research positions in the first two months of 2009.
The initial phase of the planned further development will see Almac construct a large three-story office unit to accommodate over 220 existing staff and expected recruits. For the second phase of expansion the company obtained outline planning permission for a new research facility as well as a new distribution unit to expand existing capacity.
The plans are expected to lead to additional posts across the Group comprising a mix of administrative and support staff as well as a significant proportion of graduate positions.
As well as the continued construction of their new $112 million North American Headquarters, over the past eighteen months Almac have invested around £10m at the Craigavon site in a new laboratory block and a specialist cold storage facility for clinical trial materials. When completed the new facilities are expected to represent another capital investment on a similar scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.